Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (NQF 0004)

Measure Basic Information

Name and date of specifications used: HEDIS® 2020, Volume 2 Technical Specifications for Health Plans.

URL of Specifications: N/A

Measure Type:

HEDIS ■ PQI☐ Survey☐ Other☐ Specify:

Measure Utility:

CCO Incentive■ State Quality Measure■ CMS Adult Core Set■ CMS Child Core Set☐ Other☐
Specify:

Data Source: MMIS/DSSURS

Measurement Period: January 1 – December 31, 2020 (Intake period: January 1 – November 13, 2020)

Benchmark for OHA measurement year	2016	2017	2018	2019	2020**
IET Initiation - Total - Age 13-17	41.9%	42.8%	43.4%	41.6%	TBD
IET Initiation - Total - Age 18+	37.6%	37.8%	40.7%	42.1%	TBD
IET Initiation - Total - All Age	38.0%	38.0%	40.7%	42.1%	TBD
IET Engagement - Total - Age 13-17	15.0%	13.5%	15.2%	14.3%	TBD
IET Engagement - Total - Age 18+	9.9%	9.4%	11.9%	13.3%	TBD
IET Engagement - Total - All Age	10.2%	9.7%	12.3%	13.7%	TBD
Source:	Prior year national Medicaid median				Prior year national Medicaid 75th percentile

**In 2020 CCOs must meet benchmark or improvement target for both IET and Engagement for ages 18+ to achieve measure.

Measure changes in specifications from 2018 to 2020:

OHA is using HEDIS 2020 specifications for both measurement year 2019 and 2020.

Changes from HEDIS 2019 to 2020 include:

- Removed instructions for identifying ED/observation visits that result in an inpatient stay; refer to General Guideline 44.
- Replaced MAT references with references to "medication treatment."

- Added Observation Value Set to the measure to account for the removal of observation codes from the IET Stand Alone Visits Value Set. Codes remain unchanged.
- Clarified the Engagement of AOD Treatment numerator.
- Clarified in the Notes that members in the "other drug abuse of dependence" cohort do not meet numerator criteria for Initiation of AOD Treatment of Engagement of AOD Treatment and that methadone is not included in the medication lists for the measure.
- Added ICD10 diagnosis code F12.23 to AOD Abuse and Dependence Value Set and Other Drug Abuse and Dependence Value Set.
- Added CPT code 99483 to IET Stand Alone Visits Value Set.

Changes from HEDIS 2019 to 2020 include:

- Revised the Intake Period to end on November 13 of the measurement year.
- Removed "with or without a telehealth modifier" language; refer to General Guideline 43.
- Clarified that the diagnosis must be on the discharge claim when identifying acute and nonacute inpatient discharges.
- Renamed the medication lists.
- Added "Buprenorphine injections" to the Opioid Use Disorder Treatment Medications List.
- Added HCPCS J0570, Q9991, Q9992 to AOD Medication Treatment Value Set.

Member type: CCO A ■   CCO B ■   CCO G ☐

Specify claims used in the calculation:

IET	Only use claims from matching CCO that a member is enrolled with	Denied claims included
Denominator event	N	Y
Numerator event	N	Y

Measure Details

Definitions

Intake Period	January 1–November 14 13 of the measurement year. The Intake Period is used to capture new episodes of AOD abuse and dependence.
Index Episode	The earliest eligible encounter during the Intake Period with a diagnosis of AOD abuse or dependence. For *ED visits that result in an inpatient stay*, the inpatient discharge is the Index Episode.
Index Episode Start Date (IESD)	Index Episode Start Date. The earliest date of service for an eligible encounter during the Intake Period with a diagnosis of AOD abuse or dependence. *For an outpatient, intensive outpatient, partial hospitalization, observation, telehealth, detoxification or ED visit (not resulting in an inpatient stay),* the IESD is the date of service.

	For an inpatient stay, the IESD is the date of discharge.

For an ED and observation visits that results in an inpatient stay, the IESD is the date of the inpatient discharge (an AOD diagnosis is not required for the inpatient stay; use the diagnosis from the ED or observation visit to determine the diagnosis cohort).

For direct transfers, the IESD is the discharge date from the last admission (an AOD diagnosis is not required for the transfer; use the diagnosis from the initial admission to determine the diagnosis cohort). |
| Negative Diagnosis History | A period of 60 days (2 months) before the IESD when the member had no claims/encounters with a diagnosis of AOD abuse or dependence.

For an inpatient stay, use the admission date to determine the Negative Diagnosis History.

For ED or observation visits that result in an inpatient stay, use the earliest date of service (either the ED/observation date of service or the inpatient admission date) to determine the Negative Diagnosis History.

For direct transfers, use the first admission to determine the Negative Diagnosis History. |
| Direct transfer | A direct transfer is when the discharge date from the first inpatient setting precedes the admission date to a second inpatient setting by one calendar day or less. For example:

- An inpatient discharge on June 1, followed by an admission to another inpatient setting on June 1, is a direct transfer.
- An inpatient discharge on June 1, followed by an admission to an inpatient setting on June 2, is a direct transfer.
- An inpatient discharge on June 1, followed by an admission to another inpatient setting on June 3, is not a direct transfer; these are two distinct inpatient stays.

Use the following method to identify admissions to and discharges from inpatient settings:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Identify the admission and discharge dates for the stay. |

Data elements required denominator: Members 13 years and older as of December 31st of the measurement year who have medical, pharmacy and chemical dependency (inpatient and outpatient) benefits (i.e. CCO-A and CCO-B members) with a new episode of AOD abuse or dependence during the intake period (January 1 – November 14 13 of the measurement year). Note, members in hospice are excluded from the eligible population (see detail in HEDIS 2020 General Guideline 17).

Report two **age stratifications** and the total rate:

- 13–17 years
- 18+ years
- Total

Report the following **diagnosis cohorts** for each age stratification and the total rate:

- Alcohol abuse or dependence
- Opioid abuse or dependence
- Other drug abuse or dependence
- Total

The new episode of AOD during the intake period: Follow the steps below to identify the eligible population, which is the denominator for both rates

Step 1   Identify the Index Episode. Identify all members in the specified age range who during the Intake Period had one of the following:

- An outpatient visit, telehealth, intensive outpatient visit or partial hospitalization with a diagnosis of AOD abuse or dependence. Any of the following code combinations meet criteria:
    – IET Stand Alone Visits Value Set *with* one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set, with or without a telehealth modifier (Telehealth Modifier Value Set).
    – IET Visits Group 1 Value Set *with* IET POS Group 1 Value Set *and* with one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set, with or without a telehealth modifier (Telehealth Modifier Value Set).
    – IET Visits Group 2 Value Set *with* IET POS Group 2 Value Set *and* with one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set, with or without a telehealth modifier (Telehealth Modifier Value Set).

- A detoxification visit (Detoxification Value Set) *with* one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- An ED visit (ED Value Set) *with* one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- An observation visit (Observation Value Set) *with* one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- An acute or nonacute inpatient discharge *with* one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set. To identify acute and nonacute inpatient discharges:
    1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
    2. Identify the discharge date for the stay.

- A telephone visit (Telephone Visits Value Set) **with** one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- An online assessment (Online Assessments Value Set) **with** one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

For members with more than one episode of AOD abuse or dependence, use the first episode.

For members whose first episode was an ED or observation visit that resulted in an inpatient stay, use the diagnosis from the ED or observation visit to determine the diagnosis cohort and use the inpatient discharge date as the IESD.

Step 2 Select the Index Episode and stratify based on age and AOD diagnosis cohort.

- If the member has a claim with a diagnosis of alcohol abuse or dependence (Alcohol Abuse and Dependence Value Set), place the member in the alcohol cohort.

- If the member has a diagnosis of opioid abuse of dependence (Opioid Abuse and Dependence Value Set), place the member in the opioid cohort.

- If the member has a drug abuse or dependence that is neither for opioid or alcohol (Other Drug Abuse and Dependence Value Set), place the member in the other drug cohort.

If the member has multiple substance use diagnosis on the same claim, report the member in all AOD diagnosis stratifications for which they meet criteria.

The total is not a sum of the diagnosis cohorts. Count members in the total denominator rate if they had at least one alcohol, opioid or other drug abuse or dependence diagnosis during the measurement period. Report member with multiple diagnoses on the Index Episode claim only once for the total rate for the denominator.

Step 3 Test for Negative Diagnosis History. Exclude members who had a claim/encounter with a diagnosis of AOD abuse or dependence (AOD Abuse and Dependence Value Set), AOD medication treatment (AOD Medication Treatment Value Set) or an alcohol or opioid dependency treatment medication dispensing event (Alcohol Use Disorder Treatment Medications List; Opioid Use Disorder Treatment Medications List) during the 60 days (2 months) before the IESD.

For an inpatient IESD, use the admission date to determine the 60-day Negative Diagnosis History period.

For an ED or observation visit that results in an inpatient stay, use the ED/observation date of service to determine the 60-day Negative Diagnosis History period.

Step 4 Calculate continuous enrollment. Members must be continuously enrolled for 60 days
(2 months) before the IESD through 48 days after the IESD (109 total days), with no gaps.

Required exclusions for denominator: Exclude members who use hospice services or elect to use a hospice benefit any time during the measurement year (see detail in HEDIS 2020 General Guideline 17). Exclude members who had a claim/encounter with a diagnosis of AOD abuse or dependence during the Negative Diagnosis History period (see detail in denominator section step 3).

Deviations from cited specifications for denominator: None.

Data elements required numerator:

Initiation of AOD Treatment within 14 days of the IESD

If the Index Episode was an inpatient discharge (or an ED visit that resulted in an inpatient stay), the inpatient stay is considered initiation of treatment and the member is compliant.

If the Index Episode was not an inpatient discharge, the member must initiate treatment on the IESD or in the 13 days after the IESD (14 total days). Any of the following code combinations meet criteria:

- An acute or nonacute inpatient admission **with** a diagnosis (on the discharge claim) matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set. To identify acute and nonacute inpatient admissions:

    1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).

    2. Identify the admission date for the stay.

- IET Stand Alone Visits Value Set **with** a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set, with or without a telehealth modifier (Telehealth Modifier Value Set).

- Observation Value Set **with** a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- IET Visits Group 1 Value Set **with** IET POS Group 1 Value Set **and** a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set with or without a telehealth modifier (Telehealth Modifier Value Set).

- IET Visits Group 2 Value Set **with** IET POS Group 2 Value Set **and** a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set with or without a telehealth modifier (Telehealth Modifier Value Set).

- A telephone visit (Telephone Visit Value Set) **with** a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- An online assessment (Online Assessment Value) set with a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug abuse and Dependence Value Set.

- If the Index Episode was for a diagnosis of alcohol abuse or dependence (Alcohol Abuse and Dependence Value Set) a medication treatment dispensing event (Alcohol Use Disorder Treatment Medications List) or medication treatment during a visit (AOD Medication Treatment Value Set).

- If the Index Episode was for a diagnosis of opioid abuse or dependence (Opioid Abuse and Dependence Value Set) a medication treatment dispensing event (Opioid Use Disorder Treatment Medications List) or medication treatment during a visit (AOD Medication Treatment Value Set).

  If a member is compliant for the Initiation numerator for any diagnosis cohort (i.e., alcohol, opioid, other drug) or for multiple cohorts, count the member only once in the Total Initiation numerator. The "Total" column is not the sum of the diagnosis columns.

  Exclude the member from the denominator for both indicators (Initiation of AOD Treatment and Engagement of AOD Treatment) if the initiation of treatment event is an inpatient stay with a discharge date after November 27 of the measurement year.

Engagement of AOD Treatment

Step 1 Identify all members compliant for the Initiation of AOD Treatment numerator.

  For members with initiated treatment via an inpatient admission, the 34-day period for the two engagement visits begins the day after discharge.

Step 2 Identify members whose initiation of AOD treatment was a medication treatment event (Alcohol Use Disorder Treatment Medications List; Opioid Use Disorder Treatment Medications List; AOD Medication Treatment Value Set).

  These members are numerator compliant if they have two or more engagement events where only one can be an engagement medication treatment event, beginning on the day after the initiation encounter through 34 days after the initiation event (total of 34 days).

Step 3   Identify the remaining members whose initiation of AOD treatment was *not* a medication treatment event (members not identified in step 2).

The members are numerator compliant if they meet either of the following:

- At least one engagement medication treatment event.

- At least two engagement visits.

Two engagement visits can be on the same date of service but they must be with different providers in order to count as two events. An engagement visit on the same date of service as an engagement medication treatment event meets criteria (there is no requirement that they be with different providers).

Refer to the descriptions below to identify engagement visits and engagement medication treatment events.

Any of the following beginning on the day after the initiation encounter through 34 days after the initiation event (total of 34 days) meet criteria for an **engagement visit**:

- An acute or nonacute inpatient admission *with* a diagnosis (on the discharge claim) matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set. To identify acute and nonacute inpatient admissions:
    1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
    2. Identify the admission date for the stay.

- IET Stand Alone Visits Value Set *with* a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set~~, with or without a telehealth modifier (Telehealth Modifier Value Set)~~.

- Observation Value Set *with* a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- IET Visits Group 1 Value Set *with* IET POS Group 1 Value Set *and* a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set ~~with or without a telehealth modifier (Telehealth Modifier Value Set)~~.

- IET Visits Group 2 Value Set *with* IET POS Group 2 Value Set *and* a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set ~~with or without a telehealth modifier (Telehealth Modifier Value Set)~~.

- A telephone visit (Telephone Visit Value Set) *with* a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug Abuse and Dependence Value Set.

- An online assessment (Online Assessment Value) set with a diagnosis matching the IESD diagnosis cohort using one of the following: Alcohol Abuse and Dependence Value Set, Opioid Abuse and Dependence Value Set, Other Drug abuse and Dependence Value Set.

Either of the following meeting criteria for an **engagement medication treatment event**:

- If the IESD diagnosis was a diagnosis of alcohol abuse or dependence (Alcohol Abuse and Dependence Value Set), one or more medication treatment dispensing events (Alcohol Use Disorder Treatment Medications List) or medication treatment during a visit (AOD Medication Treatment Value Set), beginning on the day after the initiation encounter through 34 days after the initiation event (total of 34 days), meets criteria for Alcohol Abuse and Dependence Treatment.

- If the IESD diagnosis was a diagnosis of opioid abuse or dependence (Opioid Abuse and Dependence Value Set), one or more medication treatment dispensing events (Opioid Use Disorder Treatment Medications List) or medication treatment during a visit (AOD Medication Treatment Value Set), beginning on the day after the initiation encounter through 34 days after the initiation event (total of 34 days), meets criteria for Opioid Abuse and Dependence Treatment

    If the member is compliant for multiple cohorts, only count the member once for the Total Engagement numerator. The Total Column is not the sum of the diagnosis columns.

Note: For members in the "other drug abuse or dependence" cohort, medication treatment does not meet numerator criteria for Initiation of AOD Treatment or Engagement of AOD Treatment.

Methadone is not included in the medication lists for this measure. Methadone for opioid use disorder is only administered or dispensed by federally certified opioid treatment programs and does not show up in pharmacy claims data. A pharmacy claim for methadone would be more indicative of treatment for pain than treatment for an opioid use disorder; therefore they are not included in the medication lists. The AOD Medication Treatment Value Set includes some codes that identify methadone treatment because these codes are used on medical claims, not pharmacy claims.

Required exclusions for numerator: None.

Deviations from cited specifications for numerator: None.

What are the continuous enrollment criteria: Member must be continuously enrolled for 60 days (2 months) before the IESD through 48 days after the IESD (109 total days), with no gaps.

What are allowable gaps in enrollment: None.

Define Anchor Date (if applicable): None.

NOTE: These standard continuous enrollment, allowable gap and anchor date criteria may be modified in 2020 to accommodate CCO membership service areas transitions.

HEDIS Value Sets and Medication list related to the measure:

Alcohol Abuse and Dependence Value Set
ICD-10-CM Diagnosis

F10.10, F10.120, F10.121, F10.129, F10.14, F10.150, F10.151, F10.159, F10.180, F10.181, F10.182, F10.188, F10.19, F10.20, F10.220, F10.221, F10.229, F10.230, F10.231, F10.232, F10.239, F10.24, F10.250, F10.251, F10.259, F10.26, F10.27, F10.280, F10.281, F10.282, F10.288, F10.29

AOD Abuse and Dependence
ICD-10-CM Diagnosis
F10.10, F10.120, F10.121, F10.129, F10.14, F10.150, F10.151, F10.159, F10.180, F10.181, F10.182, F10.188, F10.19, F10.20, F10.220, F10.221, F10.229, F10.230, F10.231, F10.232, F10.239, F10.24, F10.250, F10.251, F10.259, F10.26, F10.27, F10.280, F10.281, F10.282, F10.288, F10.29, F11.10, F11.120, F11.121, F11.122, F11.129, F11.14, F11.150, F11.151, F11.159, F11.181, F11.182, F11.188, F11.19, F11.20, F11.220, F11.221, F11.222, F11.229, F11.23, F11.24, F11.250, F11.251, F11.259, F11.281, F11.282, F11.288, F11.29, F12.10, F12.120, F12.121, F12.122, F12.129, F12.150, F12.151, F12.159, F12.180, F12.188, F12.19, F12.20, F12.220, F12.221, F12.222, F12.229, F12.23, F12.250, F12.251, F12.259, F12.280, F12.288, F12.29, F13.10, F13.120, F13.121, F13.129, F13.14, F13.150, F13.151, F13.159, F13.180, F13.181, F13.182, F13.188, F13.19, F13.20, F13.220, F13.221, F13.229, F13.230, F13.231, F13.232, F13.239, F13.24, F13.250, F13.251, F13.259, F13.26, F13.27, F13.280, F13.281, F13.282, F13.288, F13.29, F14.10, F14.120, F14.121, F14.122, F14.129, F14.14, F14.150, F14.151, F14.159, F14.180, F14.181, F14.182, F14.188, F14.19, F14.20, F14.220, F14.221, F14.222, F14.229, F14.23, F14.24, F14.250, F14.251, F14.259, F14.280, F14.281, F14.282, F14.288, F14.29, F15.10, F15.120, F15.121, F15.122, F15.129, F15.14, F15.150, F15.151, F15.159, F15.180, F15.181, F15.182, F15.188, F15.19, F15.20, F15.220, F15.221, F15.222, F15.229, F15.23, F15.24, F15.250, F15.251, F15.259, F15.280, F15.281, F15.282, F15.288, F15.29, F16.10, F16.120, F16.121, F16.122, F16.129, F16.14, F16.150, F16.151, F16.159, F16.180, F16.183, F16.188, F16.19, F16.20, F16.220, F16.221, F16.229, F16.24, F16.250, F16.251, F16.259, F16.280, F16.283, F16.288, F16.29, F18.10, F18.120, F18.121, F18.129, F18.14, F18.150, F18.151, F18.159, F18.17, F18.180, F18.188, F18.19, F18.20, F18.220, F18.221, F18.229, F18.24, F18.250, F18.251, F18.259, F18.27, F18.280, F18.288, F18.29, F19.10, F19.120, F19.121, F19.122, F19.129, F19.14, F19.150, F19.151, F19.159, F19.16, F19.17, F19.180, F19.181, F19.182, F19.188, F19.19, F19.20, F19.220, F19.221, F19.222, F19.229, F19.230, F19.231, F19.232, F19.239, F19.24, F19.250, F19.251, F19.259, F19.26, F19.27, F19.280, F19.281, F19.282, F19.288, F19.29

AOD Medication Treatment Value Set
HCPCS
H0020, H0033, J0570-J0575, J2315, Q9991, Q9992, S0109

Detoxification Value Set		
HCPCS	**ICD10PCS**	**UBREV**
H0011-H0014	HZ2ZZZZ	0116, 0126, 0136, 0146, 0156

ED Value Set	
CPT	**UBREV**
99281-99285	0450-0452, 0456, 0459, 0981

IET Visits Group 1 Value Set	IET POS Group 1 Value Set
CPT	**POS**
90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876	02, 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 52, 53, 57, 71, 72

IET Visits Group 2 Value Set	IET POS Group 2 Value Set
CPT	**POS**
99221-99223, 99231-99233, 99238, 99239, 99251-99255	02, 52, 53

IET Stand Alone Visits Value Set		
CPT	**HCPCS**	**UBREV**
98960-98962, 99078, 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99408, 99409, 99411, 99412, 99483, 99510	G0155, G0176, G0177, G0396, G0397, G0409-G0411, G0443, G0463, H0001, H0002, H0004, H0005, H0007, H0015, H0016, H0022, H0031, H0034-H0037, H0039, H0040, H0047, H2000, H2001, H2010-H2020, H2035, H2036, M0064, S0201, S9480, S9484, S9485, T1006, T1012, T1015	0510, 0513, 0515-0517, 0519-0523, 0526-0529, 0900, 0902-0907, 0911-0917, 0919, 0944, 0945, 0982, 0983

Inpatient Stay Value Set
UBREV
0100, 0101, 0110 – 0114, 0116 – 0124, 0126 – 0134, 0136 – 0144, 0146 – 0154, 0156 – 0160, 0164, 0167, 0169 – 0174, 0179, 0190 – 0194, 0199 – 0204, 0206 – 0214, 0219, 1000 – 1002

Observation Value Set
CPT
99217-99220

Online Assessments Value Set
CPT
98969, 99444

Opioid Abuse and Dependence Value Set
ICD-10-CM Diagnosis
F11.10, F11.120, F11.121, F11.122, F11.129, F11.14, F11.150, F11.151, F11.159, F11.181, F11.182, F11.188, F11.19, F11.20, F11.220, F11.221, F11.222, F11.229, F11.23, F11.24, F11.250, F11.251, F11.259, F11.281, F11.282, F11.288, F11.29

Other Drug Abuse and Dependence Value Set
ICD-10-CM Diagnosis
F12.10, F12.120, F12.121, F12.122, F12.129, F12.150, F12.151, F12.159, F12.180, F12.188, F12.19, F12.20, F12.220, F12.221, F12.222, F12.229, F12.23, F12.250, F12.251, F12.259, F12.280, F12.288, F12.29, F13.10, F13.120, F13.121, F13.129, F13.14, F13.150, F13.151, F13.159, F13.180, F13.181, F13.182, F13.188, F13.19, F13.20, F13.220, F13.221, F13.229, F13.230, F13.231, F13.232, F13.239, F13.24, F13.250, F13.251, F13.259, F13.26, F13.27, F13.280, F13.281, F13.282, F13.288, F13.29, F14.10, F14.120, F14.121, F14.122, F14.129, F14.14, F14.150, F14.151, F14.159, F14.180, F14.181, F14.182, F14.188, F14.19, F14.20, F14.220, F14.221, F14.222, F14.229, F14.23, F14.24, F14.250, F14.251, F14.259, F14.280, F14.281, F14.282, F14.288, F14.29, F15.10, F15.120, F15.121, F15.122, F15.129, F15.14, F15.150, F15.151, F15.159, F15.180, F15.181, F15.182, F15.188, F15.19, F15.20, F15.220, F15.221, F15.222, F15.229, F15.23, F15.24, F15.250, F15.251, F15.259, F15.280, F15.281, F15.282, F15.288, F15.29, F16.10, F16.120, F16.121, F16.122, F16.129, F16.14, F16.150, F16.151, F16.159, F16.180, F16.183, F16.188, F16.19, F16.20, F16.220, F16.221, F16.229, F16.24, F16.250, F16.251, F16.259, F16.280, F16.283, F16.288, F16.29, F18.10, F18.120, F18.121, F18.129, F18.14, F18.150, F18.151, F18.159, F18.17, F18.180, F18.188, F18.19, F18.20, F18.220, F18.221, F18.229, F18.24, F18.250, F18.251, F18.259, F18.27, F18.280, F18.288, F18.29, F19.10, F19.120, F19.121, F19.122, F19.129, F19.14, F19.150, F19.151, F19.159, F19.16, F19.17, F19.180, F19.181, F19.182, F19.188, F19.19, F19.20, F19.220, F19.221, F19.222, F19.229, F19.230, F19.231, F19.232, F19.239, F19.24, F19.250, F19.251, F19.259, F19.26, F19.27, F19.280, F19.281, F19.282, F19.288, F19.29

Telehealth Modifier Value Set
Modifier
95, GT

Telehealth POS Value Set
POS
02

Alcohol Use Disorder Treatment **Medications**

Description	Prescription
Aldehyde dehydrogenase inhibitor	• Disulfiram (oral)
Antagonist	• Naltrexone (oral and injectable)
Other	• Acamprosate (oral; delayed-release tablet)

Opioid Use Disorder Treatment **Medications**

Description	Prescription
Antagonist	• Naltrexone (oral and injectable)
Partial agonist	• Buprenorphine (sublingual tablet, injection, implant) • Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film)

Note HEDIS 2020 NDC lists for the medications are available at:
https://www.ncqa.org/hedis/measures/